New draft guidance aims to streamline development of cheaper versions of complex biologic medicines (used for cancer and autoimmune diseases), potentially saving millions and increasing patient access.
🔗
https://www.reuters.com/business/healthcare-pharmaceuticals/fda-ease-testing-rules-speed-biosimilar-approvals-bloomberg-news-reports-2026-03-09/
#FDAAlert #HealthNews 🌿
